Davey B. Daniel

13.4k total citations · 4 hit papers
82 papers, 3.3k citations indexed

About

Davey B. Daniel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Davey B. Daniel has authored 82 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 46 papers in Pulmonary and Respiratory Medicine and 18 papers in Cancer Research. Recurrent topics in Davey B. Daniel's work include Lung Cancer Treatments and Mutations (39 papers), Cancer Immunotherapy and Biomarkers (19 papers) and Lung Cancer Diagnosis and Treatment (18 papers). Davey B. Daniel is often cited by papers focused on Lung Cancer Treatments and Mutations (39 papers), Cancer Immunotherapy and Biomarkers (19 papers) and Lung Cancer Diagnosis and Treatment (18 papers). Davey B. Daniel collaborates with scholars based in United States, Spain and United Kingdom. Davey B. Daniel's co-authors include Maen Hussein, Tarek Mekhail, Howard West, Niels Reinmuth, David R. Spigel, Michael McCleod, Alessandro Morabito, Hans‐Georg Kopp, Achim Rittmeyer and Alona Zer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Davey B. Daniel

78 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

2019 1.1k citations Howard West, Michael McCleod et al. The Lancet Oncology profile →
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

2019 408 citations Natasha B. Leighl, Ray D. Page et al. Clinical Cancer Research profile →
Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

2013 370 citations David R. Spigel, Davey B. Daniel et al. profile →
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC

2019 305 citations Augusto Villegas, Davey B. Daniel et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Davey B. Daniel United States	19	2.2k	2.1k	688	538	362	82	3.3k
Dariusz M. Kowalski Poland	29	2.5k 1.1×	2.5k 1.2×	525 0.8×	744 1.4×	315 0.9×	173	3.8k
Venice Archer United Kingdom	9	3.6k 1.6×	3.6k 1.7×	663 1.0×	919 1.7×	276 0.8×	16	4.6k
Michael McCleod United States	17	2.5k 1.1×	1.7k 0.8×	276 0.4×	410 0.8×	341 0.9×	44	3.0k
Adrian G. Sacher Canada	29	1.7k 0.7×	2.0k 0.9×	1.0k 1.5×	809 1.5×	205 0.6×	153	3.1k
V.A. Miller United States	22	2.1k 0.9×	1.6k 0.8×	508 0.7×	924 1.7×	218 0.6×	83	3.0k
Jin‐Ji Yang China	36	3.5k 1.6×	3.9k 1.9×	1.1k 1.5×	1.2k 2.2×	306 0.8×	146	4.9k
Ernest Nadal Spain	34	1.8k 0.8×	1.8k 0.9×	815 1.2×	1.5k 2.8×	361 1.0×	169	3.6k
Joshua K. Sabari United States	28	2.2k 1.0×	1.4k 0.7×	458 0.7×	1.0k 1.9×	295 0.8×	84	3.0k
Liza C. Villaruz United States	23	1.3k 0.6×	1.2k 0.6×	422 0.6×	675 1.3×	228 0.6×	81	2.0k
Ariel López-Chávez United States	18	2.8k 1.2×	1.9k 0.9×	465 0.7×	821 1.5×	575 1.6×	41	3.7k

Countries citing papers authored by Davey B. Daniel

Since Specialization

Citations

This map shows the geographic impact of Davey B. Daniel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Davey B. Daniel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Davey B. Daniel more than expected).

Fields of papers citing papers by Davey B. Daniel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Davey B. Daniel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Davey B. Daniel. The network helps show where Davey B. Daniel may publish in the future.

Co-authorship network of co-authors of Davey B. Daniel

This figure shows the co-authorship network connecting the top 25 collaborators of Davey B. Daniel. A scholar is included among the top collaborators of Davey B. Daniel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Davey B. Daniel. Davey B. Daniel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vidal, Gregory A., Neha Jain, Aaron Fisher, et al.. (2024). Racial and Ethnic Inequities at the Practice and Physician Levels in Timely Next-Generation Sequencing for Patients With Advanced Non–Small-Cell Lung Cancer Treated in the US Community Setting. JCO Oncology Practice. 20(3). 370–377. 3 indexed citations

Spigel, David R., Byoung Chul Cho, К. К. Лактионов, et al.. (2024). LBA81 Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): Outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial. Annals of Oncology. 35. S1267–S1268. 4 indexed citations

Abrams, Joseph Y., et al.. (2023). Provider messaging for precision treatment (ProMPT): A notification pilot study to inform actionable genomic findings.. JCO Oncology Practice. 19(11_suppl). 448–448. 1 indexed citations

Schwartzberg, Lee S., Gerald Li, Khaled Tolba, et al.. (2022). Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC. JTO Clinical and Research Reports. 3(9). 100386–100386. 18 indexed citations

Yardley, Denise A., Robyn R. Young, Kerin B. Adelson, et al.. (2021). A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC). Clinical Breast Cancer. 22(3). 269–278. 9 indexed citations

Page, Ray D., Leylah Drusbosky, Victoria M. Raymond, et al.. (2021). Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non–Small Cell Lung Cancer. Clinical Lung Cancer. 23(1). 72–81. 31 indexed citations

Weiss, Jared, Jerome H. Goldschmidt, Zoran Andrić, et al.. (2021). Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies. Clinical Lung Cancer. 22(5). 449–460. 48 indexed citations

Spigel, David R., Robert M. Jotte, Santiago Ponce Aix, et al.. (2020). Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non–Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial. Clinical Lung Cancer. 22(1). 6–15.e4. 11 indexed citations

Leighl, Natasha B., Ray D. Page, Victoria M. Raymond, et al.. (2019). Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer. Clinical Cancer Research. 25(15). 4691–4700. 408 indexed citations breakdown →

10.

West, Howard, Michael McCleod, Maen Hussein, et al.. (2019). Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology. 20(7). 924–937. 1137 indexed citations breakdown →

11.

McCune, Steve, Leora Horn, Ivor Percent, et al.. (2019). EP1.12-06 New Treatment Option for ES-SCLC: Patient Characteristics and Use of an Atezolizumab Regimen in the Real-World Setting. Journal of Thoracic Oncology. 14(10). S1018–S1019. 1 indexed citations

12.

Spigel, David R., Johan Vansteenkiste, Martin Reck, et al.. (2018). P1.16-05 Effect of Induction Chemotherapy in the PACIFIC Study. Journal of Thoracic Oncology. 13(10). S629–S629. 1 indexed citations

13.

Spigel, David R., Robert M. Jotte, Santiago Ponce Aix, et al.. (2018). nab-paclitaxel + carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND.sqm study. Annals of Oncology. 29. viii749–viii750. 1 indexed citations

14.

Vansteenkiste, Johan, Jarushka Naidoo, Corinne Faivre‐Finn, et al.. (2018). MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT. Journal of Thoracic Oncology. 13(10). S370–S371. 30 indexed citations

15.

Socinski, Mark A., Mustafa Özgüroğlu, Ana Villegas, et al.. (2018). P1.16-04 Outcomes of Patients <70 or ≥70 Years of Age in PACIFIC. Journal of Thoracic Oncology. 13(10). S628–S629. 2 indexed citations

16.

Murakami, Shuji, Mustafa Özgüroğlu, Augusto Villegas, et al.. (2017). PACIFIC: A double-blind, placebo-controlled Phase III study of durvalumab as consolidation therapy after chemoradiation in patients with locally advanced, unresectable NSCLC. Annals of Oncology. 28. x122–x122. 2 indexed citations

17.

Daniel, Davey B., Charles M. Rudin, L. Hart, et al.. (2017). Results of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC). Annals of Oncology. 28. v540–v540. 15 indexed citations

18.

Johnson, Melissa L., Volker Wacheck, Maen Hussein, et al.. (2016). A phase 2 study of LY3023414 and necitumumab after first-line chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC). Annals of Oncology. 27. vi441–vi441. 3 indexed citations

19.

Yardley, Denise A., Davey B. Daniel, Mark Mainwaring, et al.. (2010). A Phase II Trial of Oxaliplatin and Trastuzumab in the Treatment of HER2-Positive Metastatic Breast Cancer. Cancer Investigation. 28(8). 865–871. 4 indexed citations

20.

Daniel, Davey B. & Jeffrey Crawford. (2006). Myelotoxicity From Chemotherapy. Seminars in Oncology. 33(1). 74–85. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact